# Commercialization of cavitation-enhancing nanodroplets for DNA sample fragmentation in NGS applications

> **NIH NIH R44** · TRIANGLE BIOTECHNOLOGY, INC. · 2021 · $1,154,747

## Abstract

PROJECT SUMMARY
 The completion of the Human Genome Project has established NGS as the gold standard technology for
personalized/precision medicine and diagnostics. Genetic testing kits are now as readily available as pregnancy
test kits, and advances in genetic analysis, gene therapy, and genetic modification in the 21st century promise to
parallel the development of transistors and integrated circuits in the 20th century. The challenge is that technology
for preparing biological samples for sequencing has not maintained a similar rapid advancement to gene
sequencing. Fragmentation of DNA randomly without bias is an essential, but difficult step in the preparation of
genomic DNA for NGS applications. A narrow range of DNA fragment lengths is required for sequencing, and
inefficient or inconsistent fragmentation will result in incomplete or excluded reads, corrupting the sequencing.
 Sonication, which fragments DNA through cavitation, is the gold standard for DNA fragmentation.
However, our customer discover interviews have reinforced that this is a significant pain point in their sample
preparation process due to its low throughput and inconsistency, particularly for industry developing large-scale
sequencing efforts.
 We have invented a novel nanodroplet reagent that enhances cavitation from an acoustic sonicator, and
greatly improves consistency and reduces time and acoustic power requirements for DNA fragmentation.
Triangle Biotechnology has licensed the patents describing this cavitation enhancing technology.
 We have achieved milestones proposed in Phase I, demonstrating product and technical feasibility. With
this SBIR Phase II, we will perform key R&D tasks, product development, and validation studies to prepare for
commercialization. Success of this project will enable a novel commercial solution for addressing market
pain points: substantially improving throughput and consistency of DNA fragmentation for NGS sample
preparation while reducing cost.

## Key facts

- **NIH application ID:** 10259765
- **Project number:** 5R44CA232902-03
- **Recipient organization:** TRIANGLE BIOTECHNOLOGY, INC.
- **Principal Investigator:** Sandeep Kasoji
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,154,747
- **Award type:** 5
- **Project period:** 2018-07-05 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10259765

## Citation

> US National Institutes of Health, RePORTER application 10259765, Commercialization of cavitation-enhancing nanodroplets for DNA sample fragmentation in NGS applications (5R44CA232902-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10259765. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*